@article{oai:phoenix.repo.nii.ac.jp:02000084,
 author = {高村, 徳人 and Takamura, Norito and 緒方, 賢次 and Ogata, Kenji and 石井, 紗綾 and Ishii, Saya and 尾﨑, 峯生 and Ozaki, Mineo and 興梠, 靖幸 and Kourogi, Yasuyuki and 徳永, 仁 and Tokunaga, Jin and 山口, 裕次 and Yamaguchi, Yuji and 園田, 純一郎 and Sonoda, Junichiro and 大崎, 卓 and Osaki, Takashi},
 journal = {九州保健福祉大学研究紀要},
 month = {Mar},
 note = {This study systematically evaluated the effects of long- and medium-chain fatty acids (LFAs and MFAs,
respectively) on human serum albumin (HSA) sites I and II and α1-acid glycoprotein (AGP) drug binding
sites using warfarin (site I) and diazepam (site II) as probes.
Free concentrations of warfarin and diazepam were quantified by UHPLC using ultrafiltration.
The results showed that the free fraction of warfarin was lower than that of the control, with increasing
[LFAs]/[HSA] (the free fraction of diazepam was markedly higher), whereas the free fraction of warfarin
was higher than that of the control, with increasing [LFAs]/[AGP] (the free fraction of diazepam was also
similar). In addition, the free fraction of warfarin was slightly higher than that of the control, with
increasing [MFAs]/[HSA] (the free fraction of diazepam was markedly higher), and the free fraction of
warfarin was slightly higher than that of the control, with increasing [MFAs]/[AGP] (the free fraction of
diazepam was also similar).
These data suggest that LFAs and MFAs either exert competitive or allosteric inhibition on the binding
of warfarin and diazepam to HSA and AGP. However, only LFAs may have a cooperative effect on
warfarin binding to HSA.},
 pages = {45--51},
 title = {ヒト血清アルブミンおよびα1-酸性糖蛋白質の薬物結合サイトに結合するワルファリンとジアゼパムに対する長鎖脂肪酸と中鎖脂肪酸の影響},
 volume = {25},
 year = {2024},
 yomi = {タカムラ, ノリト and オガタ, ケンジ and イシイ, サヤ and オザキ, ミネオ and コウロギ, ヤスユキ and トクナガ, ジン and ヤマグチ, ユウジ and ソノダ, ジュンイチロウ and オオサキ, タカシ}
}